EXPERT INTERVIEWS ON GLP-1 AND FORMOLINE L112 EXTRA

EXPERT INTERVIEWS ON GLP-1 AND FORMOLINE L112 EXTRA

Building on expert insights into GLP-1 with formoline L112 EXTRA 

Leading experts share their views on the subject of GLP-1 therapy and formoline L112 EXTRA.

EXPERT STATEMENTS
on the current status of GLP-1 therapy

EXPERT STATEMENTS
on the current status of GLP-1 therapy

Recent Developments in GLP-1 Therapy –  
an interview with Prof. Dr. Matthias Blüher

Prof. Dr. Matthias Blüher discusses the current situation in the treatment of obesity with GLP-1 receptor agonists and what could be done to think beyond GLP-1.

Dr. Petra Sandow on the current situation in general practice

In this interview, Dr. Petra Sandow explains current developments in the treatment of excess weight and obesity, as well as the significance of GLP-1 therapies from the perspective of general practice.

 Prof. Blüher on the Clinical Use of Polyglucosamine L112

In this video interview, Prof. Dr. Blüher describes his use of the active dietary fibre polyglucosamine L112, contained in formoline L112 EXTRA, in clinical practice and shares lessons learned from everyday clinical routines.

On the Role of Polyglucosamine L112  
in the Context of GLP-1 Therapy

In this interview, Prof. Dr. Blüher answers the question of how he believes that polyglucosamine L112 should be incorporated more extensively into GLP-1 therapies. 

FORMOLINE L112 EXTRA
MODE OF ACTION

FORMOLINE L112 EXTRA
MODE OF ACTION

Polyglucosamine L112, the active dietary fibre contained in formoline L112 EXTRA, uses purely physical mechanisms to bind dietary fats and cholesterol in the digestive tract. Binding lipids to the active dietary fibre L112 significantly reduces the absorption of lipids through the intestinal wall.

formoline L112 EXTRA. Class III Medical Device (CE 0123). For treatment of excess weight and obesity. Lipid binder for weight reduction and weight management with accompanying LDL cholesterol-lowering effect.  • References: Cornelli U et al. Long-Term Treatment of Overweight and Obesity with Polyglucosamine (PG L112): ... Curr Dev Nutr 2017;1(10):e000919. • Contraindications: Allergy to crustaceans. •  Side effects: Very rare: digestive problems Please also refer to the instructions for use. Some of the content in this video was generated using AI.

PRACTICE UPDATES

Stay Informed

Subscribe to our Practice Update for the latest clinical updates, research findings and educational opportunities.

Thank You for Your Interest!

Your request has been successfully submitted. You will shortly receive further information about Rethinking GLP‑1 as well as current content, services and practice-relevant updates.